NASDAQ: KZIAKazia Therapeutics Ltd Stock
$9.30-0.49 (-5.01%)
Updated Jun 13, 2025
KZIA Price
$9.30
Fair Value Price
N/A
Market Cap
$6.19M
52 Week Low
$2.86
52 Week High
$79.00
P/E
-0.41x
P/B
-0.37x
P/S
3.79x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.63M
Earnings
-$17.64M
Gross Margin
100%
Operating Margin
-1,145.67%
Profit Margin
-1,134.8%
Debt to Equity
-0.85
Operating Cash Flow
-$7M
Beta
0.98
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KZIA Overview
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KZIA's potential to beat the market
- KZIA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KZIA
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important KZIA news, forecast changes, insider trades & much more!
KZIA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KZIA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KZIA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KZIA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
KZIA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more KZIA due diligence checks available for Premium users.
Valuation
KZIA fair value
Fair Value of KZIA stock based on Discounted Cash Flow (DCF)
Price
$9.30
Fair Value
$2.31
Overvalued by
302.52%
KZIA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KZIA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.41x
Industry
-108.97x
Market
31.36x
KZIA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.37x
Industry
4.66x
KZIA's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
KZIA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
KZIA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.1M
Liabilities
$13.5M
Debt to equity
-0.85
KZIA's short-term liabilities ($10.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KZIA's long-term liabilities ($3.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KZIA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KZIA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
KZIA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KZIA vs Biotech Stocks
Kazia Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.